Surfactant apoprotein A (SP-A) reduces the inhibitory effects of plasma proteins on the surface tension lowering properties of pulmonary surfactant in vitro. To test the effects of SP-A in vivo we administered a complete natural dog lung surfactant (DLS) containing apoproteins SP-A, SP-B, and SP-C, a butanol extract of DLS (DLSE) containing only apoproteins SP-B and SP-C, and DLSE supplemented with SP-A intratracheally to prematurely delivered rabbit pups in the presence of increasing amounts of human plasma. In the absence of plasma DLS and DLSE (100 mgkg phospholipid) had comparable effects on lung mechanics (compliance during ventilation with a tidal volume of 6-7 mL/kg and quasi-static pressure-volume behavior) in this surfactant deficiency model. Plasma proteins in increasing amounts to a maximum protein concentration of 62.5 mg/mL had no effect on the response of the pups to DLS. In contrast, plasma added to DLSE in concentrations above 20 mg/mL significantly increased the peak inspiratory pressure (PIP) required to ventilate the pups with a tidal volume of 6-7 mL/kg, reduced the calculated total lung compliance, and decreased the deflation lung volumes. The inhibitory effects of plasma on DLSE were significantly less when SP-A was added to D U E (5:1, phospho1ipid:SP-A, wt:wt). The addition of SP-A to DLSE in plasma restored the activity of the extract to levels comparable to complete DLS. These results suggest that plasma can interfere with surfactant function and that SP-A has a significant protective effect for surfactant against the inhibitory effects of plasma in vivo. (Pediatr Res 37: [21] [22] [23] [24] [25] 1995) Abbreviations RDS, respiratory distress syndrome SP, surfactant apoprotein DLS, dog lung surfactant DLSE, surfactant extract PEEP, end-expiratory pressure PIP, peak inspiratory pressure Ctot, total dynamic compliance of the lung and chest wall RDS of premature newborn infants is caused by a deficiency of pulmonary surfactant (1) . Surfactant is a complex mixture of lipids and at least three specific proteins called SP-A, SP-B, and SP-C (reviewed in Ref.
2). SP-B and SP-C are small hydrophobic proteins that remain associated with surfactant lipids during organic solvent extraction (3). SP-A is a large oligomeric glycoprotein containing distinct collagen-like and lectin domains (4) . SP-A is removed from surfactant by organic solvent extraction (3) . Reconstitution studies have shown that SP-B and SP-C contribute to surfactant activity in vitro and in vivo (5, 6) . SP-A further improves the surface activity of preparations that contain SP-B and SP-C (3) and is also required to form tubular myelin (7) . Tubular adsorption of surfactant phospholipids to the alveolar fluid surface (2) . Using the prematurely delivered rabbit pup model of surfactant deficiency, Yamada et al. (8) reported that SP-A had a positive effect on lung mechanics when added back to an organic solvent extracted surfactant. Taken together these results suggest SP-A has a role in normal surfactant activity.
Many investigators have reported the inhibitory effects of plasma proteins on the biophysical activity of surfactants in vitro (9) (10) (11) (12) . Plasma proteins leak into the alveolar air spaces during lung injury and may contribute to the decreased surfactant activity of lavage fluid reported for patients with acute lung injury (13) . Plasma leakage may also be a factor contributing to the decreased response to exogenous surfactants seen in the presence of pulmonary edema (14) . The susceptibility of different surfactants to inhibition by proteins varies depending on the composition and concentration of the surfactant (15, 16).
SP-A appears to be particularly effective in protecting surfactants containing SP-B and SP-C from inhibition by plasma proteins in vitro (17, 18) . Using a premature rabbit model of surfactant deficiency we examined the effect of increasing amounts of human plasma on a complete natural dog surfactant (containing SP-A, SP-B, and SP-C), on a dog lung surfactant extract (containing only SP-B and SP-C), and on a surfactant extract supplemented with SP-A.
METHODS
Preparation of surfactants and SP-A. To obtain complete DLS, the lungs were removed from exsanguinated dogs, degassed, and lavaged three times at 4°C with 1000 mL of buffer per lavage. The buffer used for the lavage and all subsequent experiments was 5 mM Tris-HC1, 100 mM NaCl, pH 7.4. The pooled lavage was spun at 150 X for 15 min to remove cellular materials. The supernatant was spun at 20 000 X g for 15 h using a type 19 rotor in an LS5OB ultracentrifuge (Beckman, Palo Alto, CA), and the resulting pellet dispersed in buffer containing 1.64 M sodium bromide. After equilibration for 1 h, this suspension was spun at 100 000 X g for 4 h in a swinging bucket rotor. The pellicle was resuspended in buffer and washed. This pellet was resuspended in normal saline at 10 mg phospholipid/mL and used as DLS. Phospholipid concentrations were calculated from the phosphorus content (19) .
DLSE was isolated from DLS. Briefly, DLS was injected through a 22-gauge needle into a 50-fold excess by volume of 1-butanol and stirred at room temperature for 1 h. After centrifugation at 1000 X g for 20 min, the supernatant was dried under vacuum and the residue was suspended in 0.9% NaCl by rotary mixing at 42OC for 15 min. This surfactant has the same lipid composition as DLS but contains only SP-B and SP-C. SP-A was isolated from DLS. To recover SP-A, the proteins precipitated during butanol extraction were dried under nitrogen and washed twice in buffer containing 20 mM octyl-P-D-glucopyranoside. The proteins insoluble in this buffer were suspended in 5 mM Tris-HC1, pH 7.4, without NaCl and dialyzed against the same buffer for 48 h with six changes of buffer. The insoluble materials were removed by centrifugation at 100 000 X g for 30 min, and the supernatant containing SP-A was assayed for protein concentration (20) and stored in small aliquots at -20°C. We have previously reported in detail the lipid and protein composition of these surfactant fractions and the purity and activity of the SP-A isolated using these methods (3, 21) .
Preparation of samples for ventilation and surface activity studies. Aliquots of DLS or DLSE containing a total of 3 mg of phospholipid were incubated in 145 mM NaC1,5 mM CaC1, at 37°C for 10 min then centrifuged in a microfuge for 10 min. After incubation in calcium, all the phospholipid was recovered in the pellet. The pellets were resuspended in 0.3 mL of normal saline or dilutions of human plasma in normal saline. The final phospholipid concentration in all samples was 10 mg/mL. Before the addition of SP-A, 0.3 mL of DLSE in normal saline (phospholipid concentration, 10 mg/mL) was incubated at 37OC for 10 min. SP-A (20% by weight) was added to the sample. After an additional 10-min incubation at 37"C, CaCl, was added to a concentration of 5 mM and the sample centrifuged. The pellet containing DLSE with bound SP-A was resuspended in 0.3 mL of undiluted human plasma (protein concentration of 62.5 mg/mL). The human plasma used for the studies reported here was collected from a single donor by the blood bank at the University of California San Francisco. Additional studies to be reported elsewhere were performed with other plasma samples with similar results.
Surface activity. The speed of surface tension lowering by the surfactants was measured in an adsorption chamber. Samples of the three surfactants (DLS, DLSE, and DLSE plus SP-A) in various dilutions of human plasma were mixed at a phospholipid concentration of 10 mg/mL and incubated at 37°C for 1 h in either 145 mM NaCL or 145 mM NaCl, 2.5 mM CaC1,. Three mL of buffer (145 mM NaC1,2.5 mM CaCl,, 10 mM Tris-HC1, pH 7.4) was added to a circular Teflon trough 2 cm in diameter in a humidified chamber at 37OC. The sample containing 100 p g of phospholipid was carefully layered on the bottom of the trough, stirring started at 240 rpm, and surface tension continuously measured by a roughened platinum dipping plate suspended from a strain gauge (Statham Gold Cell, Hato Ray, Puerto Rico). The signal was amplified and displayed on a strip chart recorder.
Preterm ventilated rabbit model. Pregnant New Zealand White rabbits at 27 d of gestation were given 1 mL of tetracaine HCl 1% intrathecally for anesthesia. Two min before opening the uterus, each fetus received 0.5 mg of sodium pentobarbital and 4 k g of pancuronium bromide intraperitoneally through the uterine wall. Four pups with similar weights (about 30 g) were chosen from the litter for each experiment. The tracheas were cannulated with 18-gauge angiocaths and 0.3 mL of the surfactant containing 3 mg of phospholipid or 0.3 mL of the saline vehicle was instilled into the trachea. Care was taken to squeeze gently on the chest until lung fluid appeared at the catheter hub to create a fluid-to-fluid interface and optimize surfactant distribution. The instillates were pushed into the lungs by the injection of 0.4 mL of air. Care was taken to avoid reflux and loss of material. The pups were placed in individual temperature-controlled plethysmograph chambers (22) . Each pup was ventilated with a separate ventilator (Sechrist Infant Ventilator model IV-100 B, Sechrist Industries, Inc., Anaheim, CA) for 30 min with 100% oxygen at a rate of 48 breathslmin with an inspiratory time of 0.35 s, a PEEP of 4 cm H20 and a PIP of 40 cm H,O. The ECG, airway flow, tidal volume, and proximal airway pressure were recorded on each pup every 3-5 min. The PIP on each ventilator was adjusted to keep the tidal volume at 6 to 7 mL/kg. All other ventilator settings remained constant. Ctot (mL1cm H20/ kg) was calculated by dividing the tidal volume by the difference between PIP and PEEP. With the ventilatory pattern and frequency used, airway flows were nearly zero at end PIP and PEEP.
Pressure-volume measurements. After 30 min of ventilation, the endotracheal tube was plugged for 10 min to allow the lungs to degas. The animals were transferred to a water bath at 37°C and connected to an apparatus for measurement of pressure-volume characteristics as previously described (22) . The airway pressure was increased from 0 to 30 cm H20 in 5-cm H20 increments each minute. The airway pressure was then decreased at the same rate. The volume of air entering and leaving the lung was recorded just before each pressure change. 
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RESULTS
Surface activity. Plasma had a dose-dependent inhibitory effect on the surface activity of all the surfactant samples tested, but there was a marked difference between samples with respect to the plasma concentration required to inhibit activity. The surface tensions reached after 3 min of adsorption by DLS, DSLE, and DLSE plus SP-A suspended in various dilutions of plasma in either 145 mM NaCl or 145 mM NaCl, 5 mM CaCl, are shown in Figure 1 . A threshold plasma protein to phospholipid ratio (mg protein to mg phospholipid) for inhibition of adsorption was established by extending the steep part of the inhibition curves shown in Figure 1 to the x axis. The thresholds for inhibition were DLSE 0.0007, DLSE in 5 mM CaC1, 0.007, DLS 0.07, and DLSE plus SP-A in 5 mM CaCl, 0.7. With the surfactant concentration tested, the addition of SP-A to DLSE increased the threshold for plasma inhibition 70-fold, and the DLSE supplemented with SP-A had a resistance to inhibition comparable to complete DLS.
Ctot and PIP. The effects of plasma mixed with the three surfactants on lung mechanics (PIP and Ctot) during the 30 min of ventilation are shown in Figures 2-5 . Pups given DLS in saline had a significantly higher Ctot and required a significantly lower PIP than littermates given saline only. Plasma in concentrations of 6.25, 20.3, and 62.5 mg/mL had no effect on the activity of DLS during ventilation (Figs. 2 and 3) . Pups given DLSE in saline also had higher Ctot and needed lower PIP compared with littermate controls given saline only. In Plasma protein concentration (mglml) Figure 1 . Surface adsorption in vitro. Surface adsorption was measured at 37°C by recording the change in surface tension of a clean surface of Tris 10 mM, NaCl145 mM, CaC1,2.5 mM, pH 7.4, after placing the surfactant sample below the surface and starting stirring. The surface tension reached by each surfactant 3 rnin after stirring was started is shown as a function of plasma concentration in the sample. The samples (10 mg/mL phospholipid) were incubated with the various plasma concentrations for 10 rnin before placing them in the adsorption chamber. The final concentration of surfactant phospholipid in the chamber was 33 pg/mL. Filled circles, DLSE in saline; triangles, DLSE in saline + 2.5 mM CaCl,; empty circles, DLS in saline;
squares, DLSE supplemented with SP-A in saline + CaCl,. contrast to the results with DLS, the pups given DLSE showed decreased Ctot and needed higher PIP in plasma concentrations above 20.3 mg/mL (Figs. 3 and 4) . Despite this deterioration in performance with increasing plasma, DLSE in all concentrations of plasma remained significantly better than saline alone.
In a littermate comparison of the effects of undiluted plasma (62.5 mg/mL) on DLSE and DLSE supplemented with SP-A, the PIP was significantly lower in the presence of SP-A ( Pressure-volume behavior. Pups given DLSE in saline or plasma had significantly greater lung volumes at all points of the pressure-volume maneuver than pups given saline only Plasma concentration (mglml) ( Fig. 6) . A dose-dependent effect of plasma on the air volume retained during deflation was seen in the pups given DLSE (Fig. 6) . The deflation volumes from 30 to 5 cm H,O airway pressure were significantly lower in animals treated with DLSE suspended in plasma at protein concentrations of 20.8 and 62.5 mg/mL compared with DLSE suspended in normal saline or plasma at a protein concentration of 6.25 mg/mL. The addition of SP-A to DLSE significantly improved the deflation stability of the lungs in the presence of undiluted plasma (Fig. 7) .
DISCUSSION
Surfactant deficiency at birth makes it difficult for the newborn to inflate its lungs. As the infant makes increasingly vigorous attempts to ventilate noncompliant lungs, delayed adsorption of lung fluid, pulmonary edema, epithelial damage, and extravasation of plasma proteins into air spaces occur causing progressive respiratory distress. The interaction between extravasated plasma proteins and surfactant may also play a role in the pathogenesis of other forms of lung disease including pneumonia and adult RDS. Previously, many in vitro studies have shown that various substances including plasma proteins and lung edema fluid can inhibit surfactant function (9) (10) (11) (12) . In the only published report of experimental surfactant inhibition in vivo, Kobayashi et al. (23) reported that airway edema protein inhibited the activity of surfactant-CK in a model of RDS similar to that used in our study (23) . Surfactant-CK, prepared by organic solvent extraction of porcine alveolar wash surfactant, contains SP-B and SP-C. The extrac- supplemented with SP-A in 62.5 mg/mL plasma than the deflation volumes in DLSE in 62.5 mg/mL plasma or saline alone. The volumes on deflation were significantly higher (*) for DLSE in 62.5 mg/mL plasma than the deflation volumes in saline alone.
tion removes SP-A from the surfactant. Our study demonstrates for the first time that SP-A effectively protects surfactant extracts from inhibition by plasma in a premature rabbit model. Although the mechanisms underlying surfactant inhibition are not well understood, it appears that a number of different proteins prevent or decrease surfactant phospholipid adsorption when the concentration of protein is sufficiently high relative to the surfactant concentration (9) . At high protein concentrations, an interfacial film of denatured protein would form very rapidly and could prevent the adsorption of surfactant lipids. The results of our adsorption studies show plasma has a concentration-dependent effect of the activity of both complete natural surfactants and surfactant extracts. Other investigators have reported the important effects of surfactant concentration and subphase conditions on the concentration of inhibitor required for threshold inhibition in vitro (11, 24) . These results and the unknown relationship between the concentrations of surfactant and inhibitors in the lung have led to uncertainties concerning the physiologic importance of surfactant inhibition in vivo. An example of the differences between in vitro and in vivo effects is seen in our results, where potent in vitro inhibition of DLS was seen at a plasma to surfactant ratio of 0.07 but no in vivo inhibition was seen at ratios as high as 6. Because we were unable to directly measure either surfactant or protein concentrations in the lungs during ventilation, we cannot exclude rapid changes in the ratio of inhibitor to surfactant after instillation. The ventilator support, particularly the level of PEEP, used in this study may also have compensated for a loss of surfactant activity and decreased our ability to record the physiologic effects of significant changes in surfactant activity (25) .
Despite these limitations of the model, we found that the in vitro studies related well to the in vivo studies in the rank order of surfactant resistance to inhibition. DLSE is a surfactant extract containing SP-B and SP-C but no SP-A. DLSE has good activity in vitro and in vivo in the absence of plasma and as shown gives comparable results to DLS in rabbit pups with RDS ventilated with 4 cm H,O of PEEP. DLSE was the surfactant most sensitive to plasma inhibition of activity in both the surface balance and the rabbit pups. Supplementing DLSE with SP-A restored a level of resistance to inhibition by plasma comparable to complete DLS in vitro and in vivo. The mechanism by which SP-A protects surfactant activity in the presence of plasma is unknown, but it is possible that previously reported synergistic effects of SP-A on surfactant lipid adsorption rates may be important (3, 17, 18) . A more rapidly adsorbing surfactant would be expected to more effectively "compete" for the interface in the presence of other "surfaceseeking" substances including some plasma proteins. Many other mechanisms of both inhibition and protection including direct interactions between plasma and surfactant components could also be proposed.
It is hard to relate the absolute amount or concentration of plasma used in this study to levels potentially present in clinical lung disease. Seeger et al. (10) reported total protein to phospholipid ratios of 10 or more in the bronchoalveolar lavage fluid of patients with adult RDS. Using a nondilutional distal airway sampling technique, Matthay et al. (26) measured protein concentrations as high as 110 mg/mL in pulmonary edema fluid. Our experimental conditions therefore may approximate those found in some forms of lung injury. If thisis so, our results suggest that SP-A plays an important role in maintaining surfactant activity under these conditions.
